I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx.
Undervalued Stocks on NASDAQ
Today we are looking at companies that are considered undervalued based on the Analyst data in the StockCalc database.
In the table below we can see the close price and target price for these companies along with the number of analysts covering the stock. We also have included the fiscal year for the target price as sometimes these analyst targets are not for the current or even the next fiscal year.
There can be a number of reasons why a company would be on this list. What is particularly interesting are companies with a large analyst following that make this list. We need to dig deeper into these companies to understand why the difference in price versus target.
Today’s Data on NASDAQ
Today’s data is for companies listed on the NASDAQ.
| Symbol | Name | Target Year | Close Price | Target Price Mean | Currency | Target Price # of Estimates |
|---|---|---|---|---|---|---|
| GOOGL | Alphabet Inc | 2017 | 844.930000 | 981.8333 | USD | 12 |
| GOOG | Alphabet Inc | 2017 | 823.210000 | 981.8333 | USD | 12 |
| AMZN | Amazon.com Inc | 2017 | 845.040000 | 951.3000 | USD | 10 |
| CHTR | Charter Communications Inc | 2017 | 323.060000 | 366.2500 | USD | 4 |
| PCLN | The Priceline Group Inc | 2017 | 1724.130000 | 1829.2860 | USD | 7 |
| BIIB | Biogen Inc | 2017 | 288.600000 | 328.8333 | USD | 6 |
| SHPG | Shire PLC | 2017 | 180.700000 | 230.5147 | USD | 2 |
| REGN | Regeneron Pharmaceuticals Inc | 2017 | 373.500000 | 458.0000 | USD | 4 |
| ALXN | Alexion Pharmaceuticals Inc | 2017 | 131.250000 | 161.0000 | USD | 3 |
| EQIX | Equinix Inc | 2017 | 376.070000 | 420.0000 | USD | 2 |
| ORLY | O’Reilly Automotive Inc | 2017 | 271.710000 | 308.2000 | USD | 5 |
| EXPE | Expedia Inc | 2017 | 119.040000 | 150.5714 | USD | 7 |
| ULTA | Ulta Beauty Inc | 2018 | 273.430000 | 305.7500 | USD | 4 |
| ULTI | The Ultimate Software Group Inc | 2017 | 193.390000 | 240.7143 | USD | 7 |
| LOGM | LogMeIn Inc | 2017 | 91.750000 | 125.0000 | USD | 1 |
| SINA | SINA Corp | 2017 | 69.530000 | 100.0000 | USD | 1 |
| RGLD | Royal Gold Inc | 2018 | 66.050000 | 116.6266 | CAD | 2 |
| NBIX | Neurocrine Biosciences Inc | 2017 | 44.160000 | 75.0000 | USD | 3 |
| ICPT | Intercept Pharmaceuticals Inc | 2017 | 127.590000 | 190.8000 | USD | 5 |
| MSTR | MicroStrategy Inc | 2017 | 191.880000 | 225.5000 | USD | 2 |
| AGIO | Agios Pharmaceuticals Inc | 2017 | 48.440000 | 82.5000 | USD | 2 |
| ACIA | Acacia Communications Inc | 2017 | 51.950000 | 100.0000 | USD | 1 |
| SRPT | Sarepta Therapeutics Inc | 2017 | 31.110000 | 82.0000 | USD | 3 |
| GBT | Global Blood Therapeutics Inc | 2017 | 27.850000 | 60.0000 | USD | 2 |
| ATRA | Atara Biotherapeutics Inc | 2017 | 15.450000 | 47.0000 | USD | 1 |
Let’s look at a few companies…
Lets look at a couple of the companies on this list to get a better understanding of them.
BIIB:NAS Biogen
http://www.biogen.com
Biogen has 7400 employees and is headquartered in United States.
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
SHPG:NAS Shire
http://www.shire.com
Shire has 23906 employees and is headquartered in Ireland.
Shire PLC is a biotech company. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.
Free Valuation
Run a valuation on any of the companies listed above at www.stockcalc.com/valureport.aspx or subscribe at our Stockcalc Facebook Page to receive this list each day Stockcalc Reports.
The content presented here is in part from the website stockcalc.com and is provided on an as is or as available basis with all faults and may not be current in all cases. You should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment decision.